查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1791760

全球眼科臨床試驗市場

Ophthalmic Clinical Trials
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 162 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球眼科臨床試驗市場規模將達 27 億美元

全球眼科臨床試驗市場規模預計在2024年達到18億美元，預計在2024-2030年的分析期內將以6.3%的複合年成長率成長，到2030年將達到27億美元。眼科臨床試驗藥物是本報告分析的細分市場之一，預計其複合年成長率將達到7.1%，到分析期末將達到20億美元。眼科臨床試驗設備細分市場在分析期間的複合年成長率預計為4.2%。

美國市場規模估計為 4.838 億美元，中國市場預計複合年成長率為 6.1%

美國眼科臨床試驗市場規模預計2024年達到4.838億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到4.261億美元，在分析期間（2024-2030年）的複合年成長率為6.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為6.0%和5.3%。在歐洲，預計德國的複合年成長率為5.0%。

全球眼科臨床試驗市場－主要趨勢與促進因素摘要

為什麼眼科是臨床研究的溫床？

眼科學領域正在經歷模式轉移，旨在應對全球眼部疾病上升的臨床研究活動激增。由於老齡化黃斑部病變(AMD)、糖尿病視網膜病變、青光眼和乾眼症等疾病負擔的增加，眼科臨床試驗正以前所未有的速度擴大。全球人口老化是這一趨勢的主要促進因素，視力相關疾病的盛行率隨著老齡化的成長而急劇上升。同時，糖尿病和長時間使用螢幕等生活方式相關的風險因素正在推動對治療創新的需求。眼科學的獨特之處在於可以直接觀察和精確測量疾病進展，有助於準確的結果評估，使其成為對製藥和生物技術公司特別有吸引力的領域。加速研究的另一個因素是我們對基因和分子層面的眼部病理學的理解不斷加深，從而能夠進行更有針對性和個性化的治療。此外，與其他治療領域的臨床試驗相比，眼科臨床試驗由於終點明確且診斷工具標準化，通常招募速度快、時間短。這使得眼科臨床試驗在各個階段都擁有豐富的研發管線，許多產業領導者和靈活的新興企業正在投資下一代藥物、基因療法、緩釋性植入和再生醫學方法。

試驗設計的創新如何影響眼科研究？

在眼科領域，技術進步以及對高效、以患者為中心的方法日益成長的需求，正在從根本上改變臨床試驗設計的傳統模式。自適應試驗設計允許根據中期數據修改方案，因其靈活性和高效性而日益普及。同樣，分散式和混合式臨床試驗模式能夠擴大患者入組範圍，尤其是在地理分散、難以獲得專業眼科護理的人群中。行動眼科影像、遠距視力檢查應用程式和穿戴式眼壓監測儀等數位健康工具的整合，正在將即時監測功能引入臨床試驗，減少對門診就診的依賴，並提高數據收集的準確性。人工智慧 (AI) 和機器學習演算法正被用於分析影像生物標記並預測病情進展，從而最佳化患者選擇和終點確定。此類技術整合還有助於實現臨床試驗工作流程、法規提交和病患監測流程的自動化，顯著減少時間和成本負擔。此外，在試驗設計中，越來越重視使用真實世界數據 (RWD) 和真實世界證據 (RWE)，以增強外部效度和監管效度。隨著 FDA 和 EMA 等監管機構對創新臨床試驗模式的開放程度不斷提高，申辦者也感到更有信心嘗試新方法，從而推動眼科臨床試驗的進一步現代化。

哪些相關人員正在推動各個治療領域的需求？

眼科臨床試驗的需求由眾多相關人員推動，每個利害關係人在塑造研究生態系統方面都發揮著獨特而又互補的作用。製藥和生物技術公司處於前沿，致力於開發針對常見和罕見眼科疾病眼科疾病的新型療法。該行業正日益從治療症狀轉向改變和預防疾病，為抗VEGF藥物、基因療法和幹細胞療法等尖端治療方法打開了大門。眼科專業委外研發機構(CRO) 也正在成為重要的合作夥伴，在研究設計、病患招募和全球監管標準合規方面提供專業知識。學術和研究機構仍然是早期發現和轉化研究的中心，它們經常與產業相關人員組成聯盟以加速臨床開發。患者權益組織和非營利組織在製定臨床試驗優先事項方面的影響力日益增強，確保在臨床實驗方案中解決以患者為中心的結果和可及性問題。另一個主要促進因素是創業投資和私募股權公司不斷增加的投資，它們正在積極資助臨床實驗新創新興企業和平台技術。在醫療保健服務方面，綜合眼科護理創業投資和專科眼科股權在開展臨床實驗試驗方面發揮關鍵作用，它們能夠提供精準的患者群體和高品質的診斷基礎設施。這種多方相關人員的參與不僅拓寬了臨床實驗的格局，也確保了創新具有臨床相關性和商業性可行性。

推動眼科臨床試驗市場成長的具體趨勢有哪些？

眼科臨床試驗市場的成長受到與不斷發展的治療需求、技術力和行業實踐相關的多種因素的驅動。一個關鍵的成長要素是針對孤立性視網膜疾病的精準醫療和基因治療平台的快速發展，這需要專門的試驗設計和監管途徑。糖尿病等慢性全身性疾病的盛行率不斷上升，推動了以糖尿病黃斑部水腫和糖尿病視網膜病變為重點的臨床試驗。此外，全球數位螢幕使用量的激增導致乾眼症和近視的增加，促使人們廣泛研究新的治療方法。光同調斷層掃瞄(OCT)、眼底螢光和微視野等技術的進步正在提高終點準確性並且能夠對治療效果進行更細緻的評估。臨床試驗的全球化也是一個關鍵促進因素，申辦方擴大瞄準亞太、拉丁美洲和東歐的新興市場，這些市場提供大量患者群和快速招募週期。監管機構正在透過加速審查機制、有條件核准和孤兒藥認定來簡化眼科臨床試驗的核准核准，進一步獎勵創新。電子健康記錄和巨量資料分析的日益普及也有助於場地選擇、可行性評估和長期患者追蹤。最後，對生活品質 (QoL) 指標和患者報告結果的日益重視，使眼科臨床試驗與更廣泛的醫療保健價值框架相一致，從而滿足臨床和社會的期望。

部分

產品（眼科臨床試驗藥物、眼科臨床試驗設備）；階段（臨床階段、探索階段、臨床前階段）；申辦者（製藥/生物製藥公司、醫療設備公司、其他申辦者）

受訪公司範例

  • Charles River Laboratories
  • CMIC Group
  • Covance Inc.
  • ICON plc
  • IQVIA
  • Iris Pharma
  • KCR
  • Labcorp Drug Development
  • Medpace
  • Novotech
  • Ora, Inc.
  • Parexel International
  • PPD（Pharmaceutical Product Development）
  • PRA Health Sciences
  • PRC Clinical
  • QuintilesIMS
  • Syneos Health
  • TFS HealthScience
  • Worldwide Clinical Trials
  • WuXi AppTec

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global Industry Analysts 沒有遵循查詢 LLM 或特定產業SLM 的典型規範，而是建立了一個來自世界各地專家的精選內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP32424

Global Ophthalmic Clinical Trials Market to Reach US$2.7 Billion by 2030

The global market for Ophthalmic Clinical Trials estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Ophthalmic Clinical Trial Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Ophthalmic Clinical Trial Devices segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.8 Million While China is Forecast to Grow at 6.1% CAGR

The Ophthalmic Clinical Trials market in the U.S. is estimated at US$483.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$426.1 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Ophthalmic Clinical Trials Market - Key Trends & Drivers Summarized

What Makes Ophthalmology a Hotbed for Clinical Research Today?

The field of ophthalmology is undergoing a paradigm shift, with a surge in clinical research activity aimed at combating the global rise in eye-related disorders. Ophthalmic clinical trials are expanding at an unprecedented pace, driven by the increasing burden of diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and dry eye syndrome. The aging global population is a major contributor to this trend, as the prevalence of vision-related impairments escalates sharply with age. At the same time, lifestyle-related risk factors like diabetes and prolonged screen time are amplifying the need for therapeutic innovations. Ophthalmology is unique in that it allows for direct visualization and precise measurement of disease progression, which facilitates accurate outcome assessment-making it especially attractive for pharmaceutical and biotech companies. Another factor accelerating research is the evolving understanding of ocular pathophysiology at the genetic and molecular levels, enabling more targeted and individualized therapies. Furthermore, ophthalmic trials often involve faster recruitment and shorter timelines compared to trials in other therapeutic areas, due to well-defined endpoints and standardized diagnostic tools. This has attracted a mix of industry giants and nimble startups to invest in next-generation drugs, gene therapies, sustained-release implants, and regenerative medicine approaches, creating a rich pipeline of ophthalmic clinical trials across all phases.

How Are Innovations in Trial Design Reshaping Ophthalmic Research?

The traditional paradigms of clinical trial design are being radically transformed in the ophthalmology sector, spurred by technological advancements and the rising need for efficient, patient-centric methodologies. Adaptive trial designs, which allow for protocol modifications based on interim data, are gaining popularity for their flexibility and efficiency. Similarly, decentralized and hybrid clinical trial models are enabling broader patient participation, especially in geographically dispersed populations where access to specialized eye care is limited. The integration of digital health tools-such as mobile ophthalmic imaging, remote vision testing apps, and wearable intraocular pressure monitors-has brought real-time monitoring capabilities into clinical trials, reducing reliance on in-clinic visits and improving data collection accuracy. Artificial intelligence (AI) and machine learning algorithms are being deployed to analyze imaging biomarkers and predict disease progression, thereby optimizing both patient selection and endpoint determination. These technological integrations are also helping in the automation of trial workflows, regulatory submissions, and patient monitoring processes, significantly reducing time and cost burdens. Moreover, there is growing emphasis on using real-world data (RWD) and real-world evidence (RWE) in trial design to enhance external validity and regulatory relevance. As regulators such as the FDA and EMA show increasing openness to innovative trial models, sponsors are feeling more empowered to experiment with novel approaches, driving further modernization across ophthalmic clinical trials.

Which Stakeholders Are Driving Demand Across Diverse Therapeutic Fronts?

The demand for ophthalmic clinical trials is being propelled by a broad spectrum of stakeholders, each playing a distinct yet complementary role in shaping the research ecosystem. Pharmaceutical and biotechnology companies are at the forefront, striving to develop novel therapeutics that address both common and rare ocular diseases. Increasingly, there is an industry-wide shift from treating symptoms to disease modification and prevention, which has opened the door for cutting-edge therapies such as anti-VEGF agents, gene therapies, and stem cell-based interventions. Contract Research Organizations (CROs) specializing in ophthalmology have also emerged as pivotal partners, providing expertise in study design, patient recruitment, and compliance with global regulatory standards. Academic and research institutions continue to be hubs for early-stage discovery and translational research, often working in consortia with industry players to accelerate clinical development. Patient advocacy groups and nonprofit organizations are becoming influential in shaping trial priorities, ensuring that patient-centric outcomes and accessibility concerns are addressed in study protocols. Another significant driver is the rising investment from venture capital and private equity firms, which are actively funding ophthalmic startups and platform technologies. On the healthcare delivery front, integrated eye care networks and specialized ophthalmology clinics are playing a crucial role in trial execution, offering access to well-characterized patient populations and high-quality diagnostic infrastructure. The involvement of these multifaceted stakeholders is not only expanding the trial landscape but also ensuring that innovations are clinically meaningful and commercially viable.

What Specific Trends Are Accelerating Growth in the Ophthalmic Trials Market?

The growth in the ophthalmic clinical trials market is driven by several factors related to evolving therapeutic needs, technological capabilities, and industry practices. A key growth driver is the rapid development of precision medicine and gene therapy platforms tailored for monogenic retinal diseases, which require specialized trial designs and regulatory pathways. The rising incidence of chronic systemic diseases like diabetes is fueling trials focused on diabetic macular edema and diabetic retinopathy. Additionally, the global surge in digital screen usage is contributing to an increase in dry eye syndrome and myopia, prompting extensive research into novel treatment modalities. Technological advancements such as optical coherence tomography (OCT), fundus autofluorescence, and microperimetry are enhancing endpoint precision and enabling more nuanced evaluations of treatment efficacy. The globalization of clinical trials is another critical factor, with sponsors increasingly targeting emerging markets in Asia-Pacific, Latin America, and Eastern Europe to tap into large patient pools and faster recruitment cycles. Regulatory agencies are streamlining ophthalmic trial approvals through accelerated review mechanisms, conditional approvals, and orphan drug designations, further incentivizing innovation. The growing use of electronic health records and big data analytics is also supporting site selection, feasibility assessments, and long-term patient follow-up. Lastly, an increasing emphasis on quality of life (QoL) metrics and patient-reported outcomes is aligning ophthalmic trials with broader healthcare value frameworks, ensuring they meet both clinical and societal expectations.

SCOPE OF STUDY:

The report analyzes the Ophthalmic Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Ophthalmic Clinical Trial Drugs, Ophthalmic Clinical Trial Devices); Phase (Clinical Phase, Discovery Phase, Preclinical Phase); Sponsor (Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies, Other Sponsors)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Charles River Laboratories
  • CMIC Group
  • Covance Inc.
  • ICON plc
  • IQVIA
  • Iris Pharma
  • KCR
  • Labcorp Drug Development
  • Medpace
  • Novotech
  • Ora, Inc.
  • Parexel International
  • PPD (Pharmaceutical Product Development)
  • PRA Health Sciences
  • PRC Clinical
  • QuintilesIMS
  • Syneos Health
  • TFS HealthScience
  • Worldwide Clinical Trials
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Ophthalmic Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Vision Disorders Throws the Spotlight on Accelerated Ophthalmic Drug Development
    • Advances in Ocular Imaging Technologies Spur Growth in Precision-Driven Clinical Trial Endpoints
    • Patient-Centric Trial Models Expand Addressable Market Opportunity for Remote and Hybrid Ophthalmic Studies
    • Increased Focus on Rare and Genetic Eye Diseases Strengthens the Business Case for Specialized Trials
    • Biotech and Pharma Collaboration Accelerates Demand for Outsourced Ophthalmic Research Expertise
    • Digital Health Tools and Wearables Generate Opportunities for Real-Time Monitoring in Ophthalmic Trials
    • Artificial Intelligence in Image Analysis Enhances Efficiency and Accuracy of Clinical Outcome Assessments
    • Pediatric and Geriatric Trial Demographics Propel Growth in Age-Specific Study Designs and Delivery Models
    • Rising Investments in Gene Therapy and Regenerative Medicine Drive the Need for Complex Ophthalmic Trials
    • Globalization of Clinical Research Sites Sustains Growth by Broadening Access to Diverse Patient Populations
    • Risk-Based Monitoring and eSource Technologies Drive Adoption of Decentralized Clinical Trial Frameworks
    • Increased Emphasis on Quality-of-Life Metrics Generates Demand for Holistic Trial Outcomes Beyond Vision Acuity
    • Growing Involvement of Advocacy Groups and Patient Registries Strengthens Recruitment and Retention Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Clinical Trials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Ophthalmic Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Ophthalmic Clinical Trial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trial Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Ophthalmic Clinical Trial Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Clinical Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Clinical Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Discovery Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Discovery Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Preclinical Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Preclinical Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical / Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pharmaceutical / Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Sponsors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • JAPAN
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • CHINA
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • EUROPE
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • FRANCE
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • GERMANY
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • UNITED KINGDOM
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030

IV. COMPETITION